



COLLABORATIVE WORKING EXECUTIVE SUMMARY

Project Title: Pilot project of DATA-CAN's Real-Time Data Network

Project description:

The vision of DATA-CAN's Real-Time Data Network is to improve the depth of cancer intelligence for service planning and development purposes, which ultimately will have a positive outcome for NHS cancer patients. The network seeks to identify and highlight unwarranted variation in the provision of cancer care as a result of COVID-19 and beyond, through accelerating the availability of a number of core cancer service metrics.

This pilot project will involve the design of a dashboard to visualize anonymized and aggregated West Yorkshire and Harrogate Cancer Alliance data and will provide evidence to assess the utility and potential for future growth of the network.

Organisations involved:

Roche Products Ltd, Deloitte MCS Limited, DATA-CAN (hosted by UCL Partners Ltd), West Yorkshire and Harrogate Cancer Alliance have contributed resources towards this project. Roche has additionally contributed financially to the setting up of this pilot project.

Project approach:

This project will develop a dynamic dashboard of core cancer service metrics that can be displayed on the Health Data Research UK DATA-CAN website and automatically updated on a weekly basis using data submitted from NHS hospital sites across the UK. This pilot project will only include data from the West Yorkshire and Harrogate Cancer Alliance. The project will be supported by a joint steering committee from Roche and DATA-CAN, including patient representation.

Benefits to Patients:

It is expected that patients will benefit from the dashboard highlighting unwarranted variation in provision of cancer care because of COVID-19. This should allow providers to address specific variation, leading to better patient outcomes. DATA-CAN's Patient and Public Involvement and Engagement group has reviewed and approved this collaboration.

Benefit to NHS:

This pilot project will allow local and regional planners to understand and mitigate the impact of COVID-19 and other short-term changes on NHS cancer services, and will define how the Real-Time Data Network can benefit national service planners.

Benefits to Roche:

To better understand cancer services and demonstrate the value that Roche can bring by collaborating with the NHS to improve patient outcomes. Roche will not have access to any non-public NHS data.

This document has been produced by Roche Products Ltd.